Navigation Links
'Atria Bills' Get Support From Assisted Living Residents, Family Members, Senior Groups
Date:3/3/2008

Activists Rally Behind California Assembly Bills Protecting State's Elderly from Price Gouging, Ensure Safety in Emergencies

SACRAMENTO, Calif., March 3 /PRNewswire-USNewswire/ -- California seniors who feel price-gouged by providers like Atria Senior Living have teamed up with advocates and elected leaders to fight back against exorbitant cost increases, and to address serious problems with emergency preparedness. Legislation introduced by Assembly Majority Leader Karen Bass (D-Los Angeles) got strong support from Atria residents and family that travelled far and wide to the state Capitol today.

Atria is one of the largest assisted living providers in California, with 28 facilities, and is owned by a private equity buyout fund affiliated with Lazard, a Wall Street firm managing more than $140 billion globally.

Majority Leader Bass has introduced AB 2370 which requires all assisted living facilities -- or residential care facilities for the elderly (RCFEs) -- to disclose and post the last three years' worth of rent increases to better help seniors and their family make an informed decision.

"This legislation will move a step closer in developing a consistent standard of operation to eliminate questionable increases that have been reported at the range of 8 to 12 percent at some long term care facilities. This is an alarming practice when we know that the national average is 4 to 5 percent. We cannot allow these facilities to take advantage of this vulnerable community. It's imperative that we have safe, quality long-term care facilities in our state," said Majority Leader Bass.

Assemblymember Lois Wolk (D-Davis) has also introduced AB 2101 proposing similar rent increase disclosure rules, as well as providing procedures for residents to appeal those increases.

Dubbed "The Atria Bills" by activists, including SEIU Healthcare, both bills address growing resident complaints about Atria Senior Living's practic
'/>"/>

SOURCE SEIU Healthcare
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. St. Davids Medical Center First in Texas to Implement Visually Guided Catheter Ablation for Atrial Fibrillation
2. Left in the Dark and Facing Thousands in Rent Increases, Elderly Atria Senior Living Residents Protest; Call for Improvements
3. Inverness Medical Innovations Enters Into a Definitive Agreement to Acquire Matria Healthcare, Inc.
4. Activists Raise Alarm for Seniors, Deliver Carbon Monoxide Detectors to Atria Marland Place
5. CryoCor Reports Publication in Circulation for Treatment of Atrial Fibrillation
6. FDA Advisory Committee Recommends Approval of KYNAPID(TM) for Acute Atrial Fibrillation
7. Community Calls on Atria Lynbrook to Bring Back Fired Worker, Stop Discrimination and Harassment
8. Atria Senior Living Group Recognized by Arthritis Foundation as Partners In Progress
9. Atrial Fibrillation Screening Can Identify Irregular Heartbeat That Leads to Stroke
10. CryoCor Invited to Participate in FDA Advisory Panel Meeting on Atrial Fibrillation
11. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2008)...erapy given in conjunction with cancer vaccines ma...mproving the effectiveness of this promising type ...hers in the Duke Comprehensive Cancer Center. , ...hat suppress immune function and we speculated tha... in conjunction with vaccines, which work by boost...
(Date:5/15/2008)...y 15 /PRNewswire-FirstCall/ -- Digital Power,Corpo...y announced its,financial results for the first qu...ed revenue of $3,169,000 for the quarter ended,Mar...for the same quarter,last year. An operating loss ...rted, compared to an operating profit of $25,000 f...
(Date:5/15/2008)...PRNewswire/ -- JumpStart Inc., the Northeast Ohio,...the growth of innovative,early-stage businesses an...,$350,000 in CerviLenz(TM), Inc. The Cleveland-bas...Drug Administration cleared medical,device that al...th in,pregnant women, which has been established b...
(Date:5/15/2008)...Clinton Promise Comprehensive Healthcare Plans, Lo...e, Private Funding, KIRKLAND, Wash., May 15 /PRNe...oduce healthcare reform? "Probably," says Cameron ...nced long term care insurance,agencies, LTC Financ...Clinton,s, or perhaps McCain,s -- cover all health...
Breaking Medicine News(10 mins):Health News:Chemotherapy might help cancer vaccines work 2Health News:Digital Power Reports Financial Results for the First Quarter Ended March 31, 2008 2Health News:Digital Power Reports Financial Results for the First Quarter Ended March 31, 2008 3Health News:CerviLenz Receives JumpStart Investment 2Health News:CerviLenz Receives JumpStart Investment 3Health News:Don't Wait for the Election to Plan Your Long-Term Healthcare, Insurance Leader Advises 2
...azil government is up against giant drug manufactu...‘pricey’ anti-AIDS drug Efavirenz.According to the...as much as 1.59 US dollars for a 600mg pill when T...e. Negotiations between Merck and the Brazilian ...
...ry of Human Resource Development in collaboration ... launched an educational programme,// known as Ado...implemented by all the States and Union Territorie...imed at the following learning outcomes: (i) to ma...
... rice fields reverberate with the activities of fa...concern amongst the lot, for the climate// has not...s. Some farmers feel the weather has also turned c...inued undisturbed for generations, even in the fac...
...p of IT students here have developed a device that... or read//. Called 'E-Netra', it costs Rs.2,000-3,...and converts them into voice that can be heard thr... Right now it can only read text, but later it is...
Other Medicine News:Health News:Brazil Government In Contention With Merck Over Anti-AIDS Drug 2
(Date:5/15/2008)... SAN FRANCISCO, May 15 /PRNewswire-FirstCall/ ...ed that data from an ongoing Phase 1-2 clinical,tr...3100, will be presented,in an oral presentation at...SCO) Annual Meeting in Chicago., Session title:...e Cancer Session date and time: Monday, June 2 at...
(Date:5/15/2008)... MELBOURNE, Australia, May 15 /PRNewswire-Firs...ed that the abstract for its upcoming oral,present...American Society,of Clinical Oncology (ASCO) will ...ttp://www.asco.org ) from 9pm on Thursday 15 May (...I evaluation of CYT997, a novel,cytotoxic and vasc...
(Date:5/15/2008)... BRIDGEWATER, N.J., May 15 /PRNewswire-FirstCa...) announced today that findings from the,landmark ...ential therapy,for the treatment of patients with ...he risk of cardiovascular hospitalizations or deat...% (p=0.00000002), meeting the study,primary endpoi...
(Date:5/15/2008)... BOSTON, May 15 /- CenterWatch, a...ed on market research about clinical,trials, finds...ltiple EDC,(electronic data capture) systems. More...urvey indicated that they had been trained on thre...icated that the effectiveness of,their EDC trainin...
Breaking Medicine Technology:Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 2Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 3Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 2Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 3Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 4Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 5Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 6Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 7CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence 2ARUP Laboratories CEO and Co Founder Announces Retirement 4658 1ARUP Laboratories CEO and Co Founder Announces Retirement 4658 2California Stem Cell Agency Exaggerated Its Role in Funding Key Research 1831 1California Stem Cell Agency Exaggerated Its Role in Funding Key Research 1831 2U of M researchers identify process that may help treat Parkinsons spinal cord injuries 17034 1U of M researchers identify process that may help treat Parkinsons spinal cord injuries 17034 2USP announces 2008 summer internship program participants 17031 1USP announces 2008 summer internship program participants 17031 2
...bstracts highlight VELCADE efficacy in broad range...RIDGE, Mass., June 19, 2007 /PRNewswire-FirstCall/...ed that data for,VELCADE, the market leading thera...ents with previously treated multiple myeloma,(MM)...yeloma,Workshop (IMW) in Kos, Greece, June 25-30, ...
...18, 2007 /PRNewswire-FirstCall/ -- Vical,Incorpora...nGes MG,Inc. reported positive results following ...s to complete a Phase 3 trial of an,angiogenesis p...logy. Based on the findings that the primary effic...tatistical,significance and that there were no maj...
Other Medicine Technology:Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 2Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 3Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 4Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 5Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 6Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 7Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 8Vical Licensee AnGes MG Announces Positive Results of Phase 3,Angiogenesis Trial in Japan 2Vical Licensee AnGes MG Announces Positive Results of Phase 3,Angiogenesis Trial in Japan 3Vical Licensee AnGes MG Announces Positive Results of Phase 3,Angiogenesis Trial in Japan 4Vical Licensee AnGes MG Announces Positive Results of Phase 3,Angiogenesis Trial in Japan 5
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
Medicine Products: